Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 15:342:122402.
doi: 10.1016/j.carbpol.2024.122402. Epub 2024 Jun 16.

Impact of glycosylation on viral vaccines

Affiliations
Review

Impact of glycosylation on viral vaccines

Antonio Lembo et al. Carbohydr Polym. .

Abstract

Glycosylation is the most prominent modification important for vaccines and its specific pattern depends on several factors that need to be considered when developing a new biopharmaceutical. Tailor-made glycosylation can be exploited to develop more effective and safer vaccines; for this reason, a deep understanding of both glycoengineering strategies and glycans structures and functions is required. In this review we discuss the recent advances concerning glycoprotein expression systems and the explanation of glycans immunomodulation mechanisms. Furthermore, we highlight how glycans tune the immunological properties among different vaccines platforms (whole virus, recombinant protein, nucleic acid), also comparing commercially available formulations and describing the state-of-the-art analytical technologies for glycosylation analysis. The whole review stresses the aspect of glycoprotein glycans as a potential tool to overcome nowadays medical needs in vaccine field.

Keywords: Glycan analysis; Glycans; Glycoengineering; Vaccines; Virus.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Antonio Lembo reports financial support was provided by GSK Vaccines SRL. Massimiliano Biagini reports financial support was provided by GSK Vaccines SRL. Francesco Berti reports financial support was provided by GSK Vaccines SRL. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Conflict of interest This work was sponsored by GlaxoSmithKline Biologicals SA. Francesco Berti and Massimiliano Biagini are employed by the GSK group of companies.

References

Publication types

LinkOut - more resources